Immunization of disease-free melanoma patients with different HLA-A2 peptides.
Phase of Trial: Phase I/II
Latest Information Update: 18 Feb 2013
At a glance
- Drugs IMP 321 (Primary) ; IMP 321 (Primary) ; Melanoma vaccine (Primary) ; Melanoma vaccine (Primary) ; Montanide ISA-51; Montanide ISA-51
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacodynamics
- 14 Oct 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 29 Sep 2006 New trial record.